Cargando…
Mirabegron, a Selective β3-Adrenergic Receptor Agonist, as a Potential Anti-Obesity Drug
Obesity is becoming a global health epidemic. Brown and “beige” adipose tissue may produce heat, leading to energy expenditure enhancement and weight loss. Mirabegron, a selective β3-adrenergic receptor agonist, has been found to be effective as a brown adipose tissue activator, a “beige” cells stim...
Autores principales: | Dąbrowska, Anna Maria, Dudka, Jarosław |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649615/ https://www.ncbi.nlm.nih.gov/pubmed/37959362 http://dx.doi.org/10.3390/jcm12216897 |
Ejemplares similares
-
Selectivity and Maximum Response of Vibegron and Mirabegron for β(3)-Adrenergic Receptors
por: Brucker, Benjamin M., et al.
Publicado: (2022) -
Body‐weight‐independent glucose‐lowering effect of the β3‐adrenergic receptor agonist mirabegron in humans
por: Waki, Hironori, et al.
Publicado: (2021) -
Mirabegron – a selective β3-adrenoreceptor agonist for the treatment of overactive bladder
por: Bhide, Alka A, et al.
Publicado: (2012) -
Repurposing the β(3)-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease: The Beta3-LVH Phase 2b Randomized Clinical Trial
por: Balligand, Jean-Luc, et al.
Publicado: (2023) -
Agonist-Directed Desensitization of the β(2)-Adrenergic Receptor
por: Goral, Vasiliy, et al.
Publicado: (2011)